Levo Therapeutics, Inc.

Dermatology joined neurology and oncology as the drivers of the US FDA’s novel drug and biologic approvals in 2022, riding a wave of immunomodulation therapies that parallel the continuing rise of imm

Soleno Therapeutics, Inc. has unveiled promising data from two Phase III studies of its Prader-Willi syndrome candidate a year after regulators were left dissatisfied with pivotal data that were limi

The year 2022 has seen a dramatic escalation in the rate of complete response letters to approvals of novel agents, even against the backdrop of increasing CRL numbers in the past several years, a Pin

The US Food & Drug Administration’s two most recent advisory committee reviews have had more in common than meets the eye. One common feature is hard to miss: both Levo Therapeutics, Inc. ’s carbotec